Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide in Recurrent Oligodendroglial Tumors
NCT00003731Phase 2Completed
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Dec 1998
- Primary completion
- Jan 2001
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in Oligodendroglioma (OG) and oligoastrocytoma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Therapeutic Activity. Started Dec 1998; status: completed.
02
Drugs
temozolomide
03
Conditions
Oligodendroglioma (OG)oligoastrocytoma
Beyond the preview
Go deeper on NCT00003731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003731.